Page 2 - Hevolution Foundation News Today

Longevity research is booming. Scientists are looking for ways to target the basic biology of aging. And heres the exciting part: Our biological age appears to be malleable.

Longevity research is booming. Scientists are looking for ways to target the basic biology of aging. And here's the exciting part: Our biological age appears to be malleable.

Longevity research is booming. Scientists are looking for ways to target the basic biology of aging. And here's the exciting part: Our biological age appears to be malleable.

Longevity research is booming. Scientists are looking for ways to target the basic biology of aging. And here's the exciting part: Our biological age appears to be malleable.

Longevity research is booming. Scientists are looking for ways to target the basic biology of aging. And here's the exciting part: Our biological age appears to be malleable.

Longevity research is booming. Scientists are looking for ways to target the basic biology of aging. And here's the exciting part: Our biological age appears to be malleable.

With global longevity and anti-ageing market predicted to reach $183 billion by 2028, the scientific and medical community is focusing on a new paradigm in human health and a new market in life sciences with almost limitless potential.

Researchers are harnessing basic biology to develop drugs that foster healthy aging. Just don’t call them antiaging pills.

Rising demand for pharmaceutical and healthcare services in the Middle East is creating bountiful opportunities, ripe for Chinese companies with the expertise and ambition to seize them.

Exploring the powerful collaborations between scientists, investors, and the medical community in finding breakthrough treatments for major diseases, and the notion of 'healthspan'.